Event Videos

https://www.ncbi.nlm.nih.gov/pubmed/30156739 Biliary Atresia

Hepatol Res. 2018 Aug 29. doi: 10.1111/hepr.13245. [Epub ahead of print]
CYP7A1 expression in hepatocytes is retained with upregulated fibroblast growth factor 19 in pediatric biliary atresia.
Hasegawa Y1, Kawai M2, Bessho K1, Yasuda K1, Ueno T3, Satomura Y1, Konishi A1, Kimura T1, Ikeda K1, Tachibana M1, Miyoshi Y1, Michigami T2, Kondou H1,4, Ozono K1.

Abstract

AIM:

Published on: 
Aug-2018

https://www.ncbi.nlm.nih.gov/pubmed/29998462 Hepatic steatosis

Aliment Pharmacol Ther. 2018 Jul 11. doi: 10.1111/apt.14900. [Epub ahead of print]
Hepatic steatosis is highly prevalent across the paediatric age spectrum, including in pre-school age children.Dhaliwal J1,2, Chavhan GB2,3, Lurz E1,2, Shalabi A2,3, Yuen N2,3, Williams B1,2, Martincevic I1,2, Amirabadi A2,3, Wales PW2,4, Lee W2,3, Ling SC1,2, Mouzaki M5.

Abstract

BACKGROUND:
The prevalence of non-alcoholic fatty liver disease (NAFLD) in children is 8% in the general population, and 34% in the context of obesity. There is a paucity of data on the prevalence of hepatic steatosis in healthy children in Ontario.

AIMS:

Published on: 
Jul-2018

https://www.ncbi.nlm.nih.gov/pubmed/30159619

Eur Radiol. 2018 Aug 29. doi: 10.1007/s00330-018-5697-3. [Epub ahead of print]
Intrahepatic cystic biliary dilatation constitutes a significant prognostic factor in patients with primary sclerosing cholangitis.
Nguyen L1, Cazzagon N2,3, Corpechot C2, El Mouhadi S1, Lemoinne S2, Chazouillères O2, Arrivé L4,5.

Abstract

AIMS:
To evaluate the prognostic value of cystic dilatation (CD) of the intrahepatic biliary ducts in patients with primary sclerosing cholangitis (PSC).

METHODS:

Published on: 
Aug-2018

https://www.ncbi.nlm.nih.gov/pubmed/30008589 Hepatitis B

Int J Med Sci. 2018 May 22;15(8):796-801. doi: 10.7150/ijms.25047. eCollection 2018.Efficacy and safety of nucleos(t)ide analogues to prevent hepatitis B virus mother-to-childtransmission in pregnant women with high viremia: real life practice from China.Sheng Q1, Ding Y1, Li B2, Han C1, Li Y1, Zhang C1, Bai H1, Wang J1, Zhao L1, Xia T1, An Z1, Zhang M2, Dou X1.

Abstract

Published on: 
Jul-2018

https://www.ncbi.nlm.nih.gov/pubmed/30166220

Dig Liver Dis. 2018 Aug 3. pii: S1590-8658(18)30870-3. doi: 10.1016/j.dld.2018.07.033. [Epub ahead of print]

Pediatric autoimmune liver disease and extra-hepatic immune-mediated comorbidities.
Paolella G1, Farallo M1, Degrassi I1, Agostoni C1, Amoruso C1, Nuti F1, Nebbia G2.

Abstract

BACKGROUND:
Autoimmune liver disease (AILD) includes autoimmune hepatitis (AIH) and autoimmune sclerosing cholangitis (ASC). AILD is often associated with other extra-hepatic immune-mediated disorders (EDs), but there are few pediatric studies available to date. In this study we evaluated the association between AILD and EDs in our pediatric series.

METHODS:

Published on: 
Aug-2018

https://www.ncbi.nlm.nih.gov/pubmed/30009050 NAFLD

J Obes. 2018 Jun 12;2018:8626818. doi: 10.1155/2018/8626818. eCollection 2018.Dyslipidemia and Fatty Liver Disease in Overweight and Obese Children.Deeb A1, Attia S1, Mahmoud S2, Elhaj G3, Elfatih A4.

Abstract

INTRODUCTION:
Obesity is a worldwide concern. It is associated with morbidity such as dyslipidemia and liver disease. Childhood obesity has dramatically increased, particularly in the Gulf region. We aim to assess the prevalence of dyslipidemia and fatty liver disease (FLD) in overweight and obese children and analyze the association between different anthropometric measures with dyslipidemia and fatty liverdisease.

METHODS:

Published on: 
Jul-2018

https://www.ncbi.nlm.nih.gov/pubmed/30168073 Hepatitis E

Indian J Gastroenterol. 2018 Aug 31. doi: 10.1007/s12664-018-0878-1. [Epub ahead of print]
Pegylated interferon-based sequential therapy for treatment of HBeAg reactive pediatric chronic hepatitis B-First study in children..Lal BB1, Sood V1, Khanna R1, Rawat D1, Verma S1, Alam S2.

Abstract

BACKGROUND:

Our aim was to evaluate the efficacy and safety of sequential therapy using pegylated interferon (Peg-IFN) and nucleos(t)ide analogue (NA) for treatment of children in immunoactive (IA) and immunotolerant (IT) phases of chronic hepatitis B.

METHODS:

Published on: 
Aug-2018

CLF Intro movie

Financial Aid Offered by Trusts

Follow us on: